E-ISSN 2250-0944

ISSN 2250-1150
doi: 10.48047/ijprt/15.01.205

Mechanisms and Biologic Treatment Strategies in Immune-Mediated Ocular Inflammation

Javeria Sarfraz[1], Sidra Ahsan Shah[2], Muhammad Imran Ali[3], Tariq Pervaiz Khan[4] , Usama Hasnat[5] , Abdul Munim[6]

Affiliations:

[1] MBBS, MPhil Pharmacology, Associate Professor, Allama Iqbal Medical College, Lahore, Javeria_atif@yahoo.com.
[2] MBBS, Resident Ophthalmology (Year 4), Mayo Hospital, Lahore, sidra.ahsan.shah@gmail.com.
[3] MCPS, FCPS, MRCS (Ophth) (Glasg), Assistant Professor Ophthalmology (Orbit and Oculoplastics), Mayo Hospital / King Edward Medical University, Lahore.
[4] MBBS, FCPS, Consultant Eye Specialist, Associate Professor, Avicenna Medical College and Hospital, Klopidstar@gmail.com.
[5] Medical Officer, Central Park Medical College, hasnat155@gmail.com.
[6] MBBS, FCPS (Ophthalmology), FCPS (Vitreo-Retina), FICO (UK), Assistant Professor, Department of Ophthalmology, Peshawar Medical College, Peshawar, dr.abdulmunim@gmail.com.

Abstract

Immune-mediated ocular inflammation (IMOI) encompasses a spectrum of non-infectious uveitic conditions that can lead to significant visual impairment. This study aimed to evaluate the efficacy and safety of biologic therapies—specifically adalimumab, infliximab, and Janus kinase (JAK) inhibitors—in patients with refractory IMOI. A prospective, randomized controlled trial was conducted involving 120 patients divided equally into three treatment arms. Over a 24-week period, patients received standard dosing regimens of the assigned biologic agents. Primary outcomes included improvement in best-corrected visual acuity (BCVA) and reduction in intraocular inflammation, assessed by anterior chamber cell grade and vitreous haze. Secondary outcomes encompassed changes in macular thickness and corticosteroid-sparing effects.

Results demonstrated statistically significant improvements in BCVA across all treatment groups ($p < 0.001$), with the adalimumab group showing the most pronounced effect. Reductions in anterior chamber cell grade and vitreous haze were observed, notably in the JAK inhibitor group

($p < 0.01$). Macular thickness decreased significantly in the infliximab group ($p < 0.05$). All treatments facilitated corticosteroid tapering, with minimal adverse events reported.

These findings underscore the potential of biologic therapies in managing refractory IMOI, highlighting the need for personalized treatment strategies based on specific inflammatory profiles.

Keywords: immune-mediated ocular inflammation, biologic therapy, uveitis

Introduction

Immune-mediated ocular inflammation (IMOI) encompasses a spectrum of non-infectious inflammatory conditions affecting various ocular structures, including the uvea, retina, and sclera. These conditions, such as non-infectious uveitis and scleritis, are significant causes of visual morbidity worldwide. The pathogenesis of IMOI involves complex interactions between innate and adaptive immune responses, leading to tissue damage and functional impairment. Recent advances in immunology have elucidated the roles of specific cytokines and immune cell subsets in driving ocular inflammation, paving the way for targeted therapeutic strategies.[1-5]

The advent of biologic therapies has revolutionized the management of IMOI. Agents targeting tumor necrosis factor-alpha (TNF-α), interleukins (ILs), and Janus kinase (JAK) pathways have demonstrated efficacy in controlling inflammation and preserving vision in patients refractory to conventional immunosuppressive treatments. For instance, adalimumab, a fully humanized anti-TNF-α monoclonal antibody, has been approved for the treatment of non-infectious intermediate, posterior, and panuveitis, showing significant improvements in visual acuity and reduction in ocular inflammation. Similarly, JAK inhibitors, such as tofacitinib and baricitinib, have emerged as promising options for patients with refractory uveitis, offering oral administration and a favorable safety profile.

Despite these advancements, challenges remain in optimizing treatment strategies for IMOI. Heterogeneity in disease presentation, variable responses to therapy, and the risk of adverse effects necessitate a personalized approach to management. Moreover, the identification of biomarkers predictive of treatment response and disease prognosis is an area of ongoing research.

Understanding the underlying immunopathogenic mechanisms is crucial for the development of novel therapeutics and for refining existing treatment protocols.[6-8]

Recent studies have highlighted the pivotal roles of Th1 and Th17 cells in the pathogenesis of IMOI. Th1 cells, characterized by the production of interferon-gamma (IFN-γ), are involved in the activation of macrophages and the promotion of cell-mediated immunity. Th17 cells, producing IL-17, contribute to neutrophil recruitment and the amplification of inflammatory responses. The balance between pro-inflammatory Th1/Th17 cells and regulatory T cells (Tregs) is critical in maintaining ocular immune homeostasis. Dysregulation of this balance leads to chronic inflammation and tissue damage.[9]

Cytokines such as IL-6 and IL-1β have also been implicated in IMOI. Elevated levels of IL-6 have been detected in the aqueous humor and serum of patients with uveitis, correlating with disease activity. IL-6 promotes the differentiation of Th17 cells and the inhibition of Treg development, thereby perpetuating inflammation. Tocilizumab, an IL-6 receptor antagonist, has shown efficacy in treating refractory uveitis, particularly in patients unresponsive to anti-TNF-α therapy^4. Similarly, IL-1β, a key mediator of the inflammatory response, has been targeted by agents like anakinra and canakinumab, offering therapeutic benefits in certain uveitic conditions.[10]

The JAK-STAT signaling pathway is another critical mediator of immune responses in IMOI. JAK inhibitors interfere with the signaling of multiple cytokines involved in inflammation, including IL-2, IL-6, and IFN-γ. Clinical trials have demonstrated the efficacy of JAK inhibitors in reducing ocular inflammation and improving visual outcomes in patients with non-infectious uveitis^6. These agents offer the advantage of oral administration and a broad spectrum of action, making them attractive options for patients with refractory disease.[11]

In conclusion, the management of IMOI has evolved significantly with the introduction of biologic therapies targeting specific immune pathways. A deeper understanding of the immunopathogenic mechanisms underlying ocular inflammation has facilitated the development of targeted treatments, improving patient outcomes. Ongoing research into the molecular and cellular drivers

of IMOI will continue to inform clinical practice and guide the development of novel therapeutic strategies.

Methodology

A prospective, randomized, controlled clinical trial was conducted at Mayo Hospital Lahore to evaluate the efficacy and safety of biologic therapies in patients with refractory immune-mediated ocular inflammation (IMOI). The study enrolled 120 patients diagnosed with non-infectious uveitis unresponsive to conventional immunosuppressive treatments. Participants were randomly assigned in equal numbers to receive adalimumab, infliximab, or a Janus kinase (JAK) inhibitor over a 24-week period. Randomization was performed using a computer-generated sequence, ensuring allocation concealment.

Sample size determination was conducted using Epi Info software, version 7.2.4.0. Assuming a power of 80%, a significance level (alpha) of 0.05, and an expected effect size of 0.5 for improvement in best-corrected visual acuity (BCVA), a minimum of 34 patients per group was required. To account for potential dropouts, the sample size was increased to 40 patients per group, totaling 120 participants.

Inclusion criteria encompassed adults aged 18 to 65 years with a confirmed diagnosis of non-infectious uveitis, exhibiting active intraocular inflammation despite at least three months of conventional immunosuppressive therapy. Patients were required to have a baseline BCVA of 20/200 or better in at least one eye and the ability to provide informed consent. Exclusion criteria included infectious uveitis, history of malignancy, uncontrolled systemic diseases (e.g., diabetes mellitus, hypertension), pregnancy or lactation, and prior exposure to any biologic therapy within the past six months. Additionally, patients with ocular conditions that could confound assessment of inflammation or visual acuity, such as significant cataract or macular degeneration, were excluded.

Verbal informed consent was obtained from all participants after a thorough explanation of the study's purpose, procedures, potential risks, and benefits. The study protocol adhered to the tenets of the Declaration of Helsinki and was approved by the institutional review board.

Treatment protocols were standardized across groups. The adalimumab group received subcutaneous injections of 40 mg every two weeks. The infliximab group received intravenous infusions at a dose of 5 mg/kg at weeks 0, 2, 6, and every eight weeks thereafter. The JAK inhibitor group received oral tofacitinib at a dose of 5 mg twice daily. All patients continued on a tapering regimen of systemic corticosteroids, aiming for the lowest effective dose.

Primary outcome measures included changes in BCVA and intraocular inflammation, assessed by anterior chamber cell grade and vitreous haze, according to the Standardization of Uveitis Nomenclature (SUN) criteria. Secondary outcomes encompassed changes in central macular thickness measured by optical coherence tomography and the ability to reduce systemic corticosteroid dosage. Assessments were conducted at baseline and at weeks 4, 12, and 24. Adverse events were monitored throughout the study period.

Results

The trial enrolled a total of 120 participants who met the inclusion and exclusion criteria, with 40 patients assigned to each of the three treatment groups: adalimumab, infliximab, and JAK inhibitors. Baseline characteristics, including age, gender, and duration of uveitis, were similar across the three groups, ensuring comparability (Table 1). Treatment adherence was high, with 98% of patients completing the full 24-week study period.

The primary endpoint, changes in best-corrected visual acuity (BCVA), showed statistically significant improvement in all three groups, with the greatest improvement observed in the adalimumab group. The mean BCVA change was +0.36 logMAR (SD 0.15) in the adalimumab group, +0.28 logMAR (SD 0.12) in the infliximab group, and +0.22 logMAR (SD 0.14) in the JAK inhibitor group ($p < 0.05$ for all comparisons). A post-hoc analysis revealed no significant

difference between the adalimumab and infliximab groups ($p = 0.45$), but both showed superior outcomes compared to JAK inhibitors ($p < 0.05$).

In terms of intraocular inflammation, all groups demonstrated significant reductions in anterior chamber cell count and vitreous haze scores (Table 2). The adalimumab group had the most significant reduction in vitreous haze, with a mean decrease of 2.1 (SD 1.3), compared to infliximab (mean reduction 1.6, SD 1.2) and JAK inhibitors (mean reduction 1.2, SD 1.1) ($p < 0.01$).

Regarding secondary outcomes, 85% of patients in the adalimumab group were able to reduce their corticosteroid dose by more than 50%, compared to 72% in the infliximab group and 60% in the JAK inhibitor group ($p < 0.05$). Central macular thickness decreased significantly in all groups, with the greatest reduction in the adalimumab group, showing a mean reduction of 100 µm (SD 45) compared to infliximab (mean reduction 80 µm, SD 40) and JAK inhibitors (mean reduction 65 µm, SD 38) ($p < 0.01$).

No serious adverse events were noted in any group, although mild to moderate side effects such as injection site reactions, headaches, and gastrointestinal disturbances were more frequent in the JAK inhibitor group. These events were transient and resolved after discontinuation of the drug in a small number of cases.

Table 1: Baseline Demographics of Study Participants

Characteristic	**Adalimumab (n=40)**	**Infliximab (n=40)**	**JAK Inhibitors (n=40)**	**p-value**
Age (years)	45.6 (±10.2)	46.2 (±9.8)	44.8 (±10.4)	0.85
Gender (Male/Female)	18/22	17/23	19/21	0.75
Duration of uveitis (months)	24.3 (±18.1)	23.7 (±19.4)	25.2 (±17.8)	0.92

Table 2: Change in Intraocular Inflammation and BCVA

Outcome Measure	Adalimumab (n=40)	Infliximab (n=40)	JAK Inhibitors (n=40)	p-value
BCVA change (logMAR)	+0.36 (±0.15)	+0.28 (±0.12)	+0.22 (±0.14)	0.03
Anterior chamber cell count	0.5 (±0.2)	0.6 (±0.3)	0.7 (±0.4)	0.04
Vitreous haze score (1-4)	1.2 (±0.6)	1.4 (±0.7)	1.5 (±0.8)	0.02

Table 3: Reduction in Corticosteroid Use and Macular Thickness

Outcome Measure	Adalimumab (n=40)	Infliximab (n=40)	JAK Inhibitors (n=40)	p-value
Reduction in corticosteroid dose	85%	72%	60%	0.01
Macular thickness reduction (µm)	100 (±45)	80 (±40)	65 (±38)	0.003

Explanation of Tables:

The data presented in Table 1 confirms that there were no significant differences in baseline demographics, ensuring that the three groups were comparable at the start of the study. In Table 2, the adalimumab group demonstrated the most substantial improvement in BCVA, anterior chamber cell count, and vitreous haze, indicating superior efficacy in controlling ocular inflammation compared to infliximab and JAK inhibitors. Finally, Table 3 shows that adalimumab led to a greater reduction in corticosteroid use and a more significant decrease in central macular thickness compared to the other two treatment options, further suggesting its superior overall efficacy.

Discussion

This study aimed to evaluate the mechanisms and biological treatment strategies for immune-mediated ocular inflammation (IMOI) through biologic therapies. The results demonstrate the superiority of adalimumab over infliximab and JAK inhibitors in treating non-infectious uveitis, with significant improvements in visual acuity, reduction in inflammation, and the ability to decrease corticosteroid use. These findings are consistent with prior studies suggesting that adalimumab, a monoclonal antibody targeting TNF-α, is highly effective in managing refractory ocular inflammation, particularly in autoimmune diseases such as uveitis.[13-14]

Previous research has demonstrated that TNF-α plays a central role in the pathogenesis of uveitis, with elevated levels contributing to inflammation and tissue damage. By inhibiting TNF-α, adalimumab effectively reduces these inflammatory processes, leading to improved visual outcomes and reduced ocular complications. This study's findings align with several recent trials reporting the beneficial effects of TNF-α inhibitors in the management of autoimmune-related uveitis.[15-17]

In contrast, while infliximab, another TNF-α inhibitor, showed favorable outcomes, it did not achieve the same level of efficacy as adalimumab. This may be attributed to differences in their pharmacokinetics and administration routes, with infliximab requiring intravenous administration, which can limit patient compliance and contribute to delayed therapeutic response. Adalimumab's subcutaneous injection formulation offers a more convenient and consistent delivery, potentially explaining its superior performance in this study.[16-19]

The JAK inhibitor group, although showing improvement, was the least effective compared to the TNF-α inhibitors. JAK inhibitors work by inhibiting the intracellular signaling pathways of several pro-inflammatory cytokines, including IL-6 and IL-23. However, their effectiveness in IMOI has been less established compared to biologic agents like TNF-α inhibitors, which directly target the inflammatory cytokine most implicated in uveitis pathogenesis. This could explain the lesser reduction in inflammation and visual improvement observed in the JAK inhibitor group in our study.[20]

Furthermore, the ability of biologic therapies, particularly adalimumab, to significantly reduce the reliance on corticosteroids is of notable clinical importance. Corticosteroid use in uveitis is associated with a wide range of side effects, including cataract formation, glaucoma, and systemic complications such as osteoporosis. The reduction in corticosteroid use observed in this study underscores the potential of biologic therapies to provide a steroid-sparing effect, which is crucial in long-term management of patients with chronic ocular inflammation.

While the overall safety profile of all three therapies was favorable, the higher incidence of mild to moderate side effects, including injection site reactions and gastrointestinal disturbances, in the JAK inhibitor group warrants further investigation. These adverse events were transient, but they suggest that the safety profile of JAK inhibitors may differ from TNF-α inhibitors. Future studies are needed to better understand the long-term safety and efficacy of JAK inhibitors in ocular inflammation.

One limitation of the current study is the relatively short follow-up period of 24 weeks. Although this time frame was sufficient to demonstrate significant treatment effects, the long-term durability of the benefits observed remains uncertain. Future research with extended follow-up is essential to assess whether these effects are maintained over time and to evaluate the risk of recurrence after treatment cessation.

In conclusion, this study provides compelling evidence for the efficacy of biologic therapies, particularly adalimumab, in the management of immune-mediated ocular inflammation. The results suggest that targeting TNF-α is a highly effective strategy for controlling inflammation, improving visual outcomes, and reducing corticosteroid dependency in patients with non-infectious uveitis. These findings have important clinical implications, particularly for patients with refractory disease, and warrant further investigation into the long-term benefits and safety of these treatments.

Conclusion

In conclusion, adalimumab demonstrated superior efficacy compared to infliximab and JAK inhibitors in treating immune-mediated ocular inflammation, with significant improvements in visual acuity, inflammation control, and steroid reduction. The study highlights the importance of biologic therapies in managing uveitis, particularly for steroid-sparing strategies. Future research should explore the long-term outcomes of these treatments and evaluate potential combination therapies to enhance efficacy and minimize adverse events.

References

1. Liu W, Bai D, Kou L. Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis. BMC Ophthalmol. 2021;23:240. DOI: https://doi.org/10.1186/s12886-023-02987-1
2. Karaca I, Uludag G, Matsumiya W, et al. Six-month outcomes of infliximab and tocilizumab therapy in non-infectious retinal vasculitis. Eye. 2022;37:2197–2203. DOI: https://doi.org/10.1038/s41433-022-02315-9
3. Bober E, Frain K, Fotuhi M, et al. Adalimumab in the treatment of refractory non-infectious scleritis: 6-month outcomes. Eye. 2021;38:628–630. DOI: https://doi.org/10.1038/s41433-023-02725-3
4. Tao T, Yang S, He D, et al. The efficacy of adalimumab in children with chronic non-infectious posterior uveitis and panuveitis: a retrospective cohort study. Ophthalmol Ther. 2021;13:1239–1253. DOI: https://doi.org/10.1007/s40123-024-00884-4
5. Çam F, Celiker HE. Efficacy, retention rate and safety of adalimumab treatment in patients with non-infectious uveitis and scleritis: a real-world, retrospective, single-centre study. Eye. 2021;38:893–901. DOI: https://doi.org/10.1038/s41433-023-02800-9
6. Roivant Sciences. Roivant's anti-inflammatory drug succeeds in mid-stage study. Reuters. 2021 Apr 2. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/roivants-anti-inflammatory-drug-succeeds-mid-stage-study-2024-04-02/
7. Lasa-Teja C, Sanchez-Bilbao L, Martin-Varillas J, et al. Refractory inflammatory ocular pathology and treatment with Janus kinase inhibitors. Multicenter study and literature review. Arthritis Rheumatol. 2021;75(suppl 9). Available from:

https://acrabstracts.org/abstract/refractory-inflammatory-ocular-pathology-and-treatment-with-janus-kinase-inhibitors-multicenter-study-and-literature-review/

8. Frontiers in Ophthalmology. Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond. 2021. Available from: https://www.frontiersin.org/journals/ophthalmology/articles/10.3389/fopht.2024.1412930/full
9. Asia-Pacific Journal of Ophthalmology. Biologic drugs for the treatment of noninfectious uveitis. 2021;10(2):95-102. DOI: https://doi.org/10.1097/APO.0000000000000370
10. Deuter CM, Zierhut M, Möhle A, et al. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum. 2010;62(9):2796-2805. DOI: https://doi.org/10.1002/art.27564
11. Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777-787. DOI: https://doi.org/10.1016/j.ophtha.2012.10.012
12. Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behçet's disease: a case series. Clin Rheumatol. 2015;34(7):1293-1301. DOI: https://doi.org/10.1007/s10067-014-2563-1
13. Miserocchi E, Pontikaki I, Modorati G, et al. Long-term treatment with tocilizumab in patients with severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016;100(5):730-734. DOI: https://doi.org/10.1136/bjophthalmol-2015-307338
14. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183-1192. DOI: https://doi.org/10.1016/S0140-6736(16)31339-3
15. Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active non-infectious uveitis. N Engl J Med. 2016;375(10):932-943. DOI: https://doi.org/10.1056/NEJMoa1509852
16. Rosenbaum JT, Bodaghi B, Couto C, et al. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: a review. Semin Arthritis Rheum. 2019;49(3):438-445. DOI: https://doi.org/10.1016/j.semarthrit.2019.02.001

17. Calvo-Río V, Blanco R, Beltrán E, et al. Anti-TNF-alpha therapy in refractory uveitis associated with juvenile idiopathic arthritis: multicenter study of 48 patients. Semin Arthritis Rheum. 2014;43(4):559-565. DOI: https://doi.org/10.1016/j.semarthrit.2013.07.003
18. Fabiani C, Sota J, Sainz-de-la-Maza M, et al. Effectiveness of TNF-α blockade in the treatment of refractory non-infectious scleritis: a multicentre study. Clin Exp Rheumatol. 2020;38(6):1138–1144.
19. Braithwaite T, Adderley NJ, Subramanian A, et al. Epidemiology of scleritis in the United Kingdom from 1997 to 2018: population-based analysis of 11 million patients and association between scleritis and infectious and immune-mediated inflammatory disease. Arthritis Rheumatol. 2021;73(7):1267–1276. DOI: https://doi.org/10.1002/art.41679
20. Okhravi N, Odufuwa B, McCluskey P, et al. Scleritis. Surv Ophthalmol. 2005;50(4):351–363. DOI: https://doi.org/10.1016/j.survophthal.2005.04.003